Current clinical trials
ALLG clinical trial HD10: Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD
Trial Lead: Professor Mark Hertzberg
HD10 is an international, prospective, randomised and open-label phase III trial. The aim of this trial is to prove that the new chemotherapy regimen BrECADD, is non-inferior to BEACOPP as first line treatment in advanced stage classical Hodgkin lymphoma, each followed by radiotherapy to PET-positive residual lesions greater than or equal to 2.5cm, to improve PFS rates.
The co-primary endpoint for this trial is the rate of serious treatment-related morbidity- “TRMorbidity”. Secondary Endpoints are Overall Survival, Tumour response (final treatment outcome), Infertility rate at 1 year, Secondary Malignancies.
The clinical trial will recruit approximately 90 patients across 16 Australasian sites. The timeline for the recruitment of patients is 2018 to mid-2020.
ALLG clinical trial NHL30: PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma.
Trial Lead: Associate Professor Judith Trotman
The study aims to use a [18F]-Fluoro-deoxyglucose (FDG) PET-computed tomography (CT) response-adapted approach, with two randomisations aimed to improve the outcome of patients who remain PET-positive after initial immunochemotherapy, who have been demonstrated to have a very poor outcome, (a superiority study), and to minimise further treatment for good prognosis patients who become PET-negative (a non-inferiority study). In addition, a comprehensive set of correlative samples will be collected to define immunologic biomarkers of response to treatment.
The clinical trial will recruit approximately 37 patients across 6 Australasian sites. The timeline for the recruitment of patients is 2018 to 2021.
Visit the ALLG website or talk to your haematologist if you’re interested in signing up to any of these trials.
Developed by the Leukaemia Foundation in consultation with people living with a blood cancer, Leukaemia Foundation support staff, haematology nursing staff and/or Australian clinical haematologists. This content is provided for information purposes only and we urge you to always seek advice from a registered health care professional for diagnosis, treatment and answers to your medical questions, including the suitability of a particular therapy, service, product or treatment in your circumstances. The Leukaemia Foundation shall not bear any liability for any person relying on the materials contained on this website.